Investors can expect a company’s stock to rise or fall based on the buying and selling of stock by its insiders. Esperion Therapeutics Inc shares valued at $1,469 were purchased by Looker Benjamin on Jul 17 ’25. At $1.13 per share, Looker Benjamin acquired 1,304 shares.
Also, Halladay Benjamin purchased 11 shares, netting a total of over 12 in proceeds.
Before that, Looker Benjamin had sold 6,422 shares from its account. In a trade valued at $7,398, the General Counsel traded Esperion Therapeutics Inc shares for $1.15 each. Upon closing the transaction, the insider’s holdings decreased to 6,422 shares, worth approximately $0.5 million.
As published in their initiating research note from Goldman on December 18, 2024, Esperion Therapeutics Inc [ESPR] has been a Neutral and the price target has been revised to $4. Analysts at Cantor Fitzgerald started covering the stock with ‘”an Overweight”‘ outlook in a report released in mid December. As of June 20, 2024, BofA Securities has decreased its “Neutral” rating to a “an Underperform” for ESPR. Earlier on January 03, 2024, BofA Securities downgraded its rating. Their new recommendation was “a Neutral” for ESPR stock which previously was a “a Buy”.
Analyzing ESPR Stock Performance
On last trading session,, Esperion Therapeutics Inc [NASDAQ: ESPR] rose 10.71% to $1.24. The stock’s lowest price that day was $1.105, but it reached a high of $1.27 in the same session. Over the course of the year, Esperion Therapeutics Inc shares have dropped approximately -50.40%.
Support And Resistance Levels for Esperion Therapeutics Inc (ESPR)
RSI (Relative Strength Index) is 60.85 on the 14-day chart, showing neutral technical sentiment.
Is Esperion Therapeutics Inc subject to short interest?
Stocks of Esperion Therapeutics Inc saw a sharp steep in short interest on 2025-06-13 dropping by -3.83 million shares to 24.11 million. Data from Yahoo Finance shows that the short interest on 2025-05-15 was 27.95 million shares. A decline of -15.89% in short interest reflects a positive sentiment towards the stock. Despite the fact that short shares comprise just 4.98 of the overall float, the days-to-cover ratio (short ratio) decline to 4.98.
Which companies own the most shares of Esperion Therapeutics Inc (ESPR)?
In terms of Esperion Therapeutics Inc share price expectations, FactSet research, analysts set an average price target of 12 in the next 12 months, up nearly 971.43% from the previous closing price of $1.12. Analysts anticipate Esperion Therapeutics Inc stock to reach 20 by 2025, with the lowest price target being 8. In spite of this, 8 analysts ranked Esperion Therapeutics Inc stock as Buy at the end of 2025.
